Adintrevimab Biosimilar – Anti-Spike RBD mAb – Research Grade

Introduction to Adintrevimab Biosimilar – Anti-Spike RBD mAb – Research Grade Adintrevimab Biosimilar, also known as Anti-Spike RBD mAb, is a monoclonal antibody (mAb) that specifically targets the receptor-binding domain (RBD) of the Spike protein of the SARS-CoV-2 virus. It is a research grade antibody that has shown promising results in pre-clinical studies and is being developed as a potential therapeutic option for COVID-19. In this article, we will discuss the structure, activity, and potential applications of Adintrevimab Biosimilar.

Structure of Adintrevimab Biosimilar

Adintrevimab Biosimilar is a fully human mAb, meaning it is derived from human cells and has a lower risk of immune reactions compared to antibodies derived from other species. It is composed of two identical heavy chains and two identical light chains, each with a specific amino acid sequence that gives the antibody its unique structure. The heavy and light chains are connected by disulfide bonds, and the variable regions of the antibody, responsible for binding to the Spike RBD, are located at the tips of the arms.

Activity of Adintrevimab Biosimilar

Adintrevimab Biosimilar is designed to bind specifically to the RBD of the Spike protein, which is responsible for attaching to the ACE2 receptor on human cells and facilitating viral entry. By binding to the RBD, Adintrevimab Biosimilar prevents the virus from attaching to and infecting human cells, thus inhibiting viral replication. This mechanism of action is similar to that of natural antibodies produced by the immune system in response to infection.

In pre-clinical studies, Adintrevimab Biosimilar has shown high affinity and specificity for the Spike RBD, effectively blocking viral entry and reducing viral load. It has also demonstrated the ability to activate the immune system and promote the production of other antibodies, further enhancing its antiviral activity.

Potential Applications of Adintrevimab Biosimilar

Adintrevimab Biosimilar is being developed as a potential therapeutic option for COVID-19, with the goal of reducing disease severity and preventing severe complications. It is currently in pre-clinical studies, and if successful, it may progress to clinical trials and eventually be approved for use in patients.

In addition to its potential use as a therapeutic, Adintrevimab Biosimilar can also be used as a research tool for studying the SARS-CoV-2 virus and its interaction with the human immune system. Its high specificity and affinity for the Spike RBD make it a valuable tool for studying viral entry and potential targets for antiviral therapies.

Conclusion

Adintrevimab Biosimilar, also known as Anti-Spike RBD mAb, is a research grade monoclonal antibody that specifically targets the RBD of the SARS-CoV-2 Spike protein. Its unique structure and mechanism of action make it a promising candidate for the treatment of COVID-19, and it also has potential applications as a research tool. Further studies and clinical trials will determine the efficacy and safety of Adintrevimab Biosimilar, but it holds great promise in the fight against the current pandemic.

ProteoGenix catalogue number PX-TA1803. For research use only.

Target: Adintrevimab Biosimilar – Anti-Spike RBD mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet